Mein Warenkorb

Neuropilin-1

Neuropilin-1 Molekülinformation

Englischer NameNeuropilin-1Anzahl der inverkehr gebrachten Arzneimittel0
Anzahl der klinischen Arzneimittel1Target-AliasBDCA4,NP1,Neuropilin-1,NRP1,CD304,VEGF165R,Neuropilin 1,Vascular Endothelial Cell Growth Factor 165 Receptor,NRP,Transmembrane Receptor,CD304 Antigen
Höchste Forschungs- und EntwicklungsphasePhase 2 Clinical
Englischer NameNeuropilin-1
Target-AliasBDCA4,NP1,Neuropilin-1,NRP1,CD304,VEGF165R,Neuropilin 1,Vascular Endothelial Cell Growth Factor 165 Receptor,NRP,Transmembrane Receptor,CD304 Antigen
Anzahl der inverkehr gebrachten Arzneimittel0
Anzahl der klinischen Arzneimittel1
Höchste Forschungs- und EntwicklungsphasePhase 2 Clinical

Neuropilin-1 Produktliste

  • Attribut

    Protein (5)

  • Produktbibliothek

    Online (5)

  • Spezies

    Human (3)Mouse (2)

  • Etikett

    His Tag (2)Fc Tag (1)His Tag & Avi Tag (1)Mouse IgG Fc Tag (1)

  • Marker

    Unconjugated (4)Biotin-labeled (1)

Neuropilin-1 Molekülhintergrund

Neuropilin-1 (NRP1) is also known as Vascular endothelial cell growth factor 165 receptor (VEGF165R), CD antigen CD304, which belongs to the neuropilin family. The membrane-bound isoform 1 is a receptor involved in the development of the cardiovascular system, in angiogenesis, in the formation of certain neuronal circuits and in organogenesis outside the nervous system. It mediates the chemorepulsant activity of semaphorins. It binds to semaphorin 3A, The PLGF-2 isoform of PGF, The VEGF-165 isoform of VEGF and VEGF-B. Coexpression with KDR results in increased VEGF-165 binding to KDR as well as increased chemotaxis. It may regulate VEGF-induced angiogenesis. The soluble isoform 2 binds VEGF-165 and appears to inhibit its binding to cells.

Neuropilin-1 Molekülalias

NRP1,Neuropilin-1,NRP,VEGF165R,CD304

Klinische Arzneimittelinformation

Englischer NameForschungscodeForschungsphaseFirmaIndikationenKlinische Studie
CertepetideCEND-1; iRGD; CIND-1; LSTA1; QLC12102; LSTA-1Phase 2 ClinicalDrugcendr IncAppendiceal Neoplasms; Bile Duct Neoplasms; Carcinoma, Ovarian Epithelial; Carcinoma, Pancreatic Ductal; Cholangiocarcinoma; Colonic Neoplasms; Colorectal Neoplasms; Gallbladder Neoplasms; Neoplasm Metastasis; Pancreatic Neoplasms; Triple Negative Breast Neoplasms
Details
  • Molekülinformation
  • Produktliste
  • Klinische Arzneimittelinformation
Kontaktieren Sie uns